-
Pufang Biotech announced that it will showcase its new drug linker technology aimed at expanding
Time of Update: 2021-11-05
Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.
-
PD-1 inhibitor combined with ADC opens up a new direction for the treatment of advanced
Time of Update: 2021-11-04
In the past few decades, the traditional first-line treatment program is mainly cisplatin-based systemic therapy, including gemcitabine + cisplatin (GC) regimen, dose-enhanced methotrexate + adriamycin + vincristine + cisplatin Platinum (ddMVAC) programs have certain clinical benefits[1,2], and the objective response rate (ORR) is about 40%, but the 5-year overall survival rate of mUC is still <10%[3] .
-
One after another, Hengrui's new ADC drug has been approved for clinical use for the first time
Time of Update: 2021-11-02
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn October 25, CDE official website showed that Hengrui Medicine's SHR-A1921 clinical trial application was approved by the China Food and Drug Administration .
-
2021 CSCO Professor Sheng Xinan: Immunization combined with ADC, a new breakthrough in the treatment of metastatic urothelial cancer
Time of Update: 2021-10-21
. Yimaitong: At this year’s CSCO meeting, you reported a Phase 1B/II clinical study on the safety and effectiveness of vedicitumumab combined with teriprizumab in the treatment of patients with locally advanced or metastatic urothelial cancer Please introduce the latest data of this study.
-
ADC combination therapy is expected to become a new option for the treatment of lung cancer patients
Time of Update: 2021-10-21
01ADC and anti-angiogenesis drug joint research is underway The results of the extended cohort study (NCT02187848) showed that [5], SAR408701 has good anti-tumor activity in advanced non-squamous NSCLC patients with high CEACAM5 expression who have previously received multiple lines of treatment .
-
Prof. Zhimin Shao: A new generation of ADC drugs enables HER2-positive breast cancer treatment to enter a new stage
Time of Update: 2021-09-30
1 months DESTINY-Breast04 is an exploration DS8201 has received ≥1 line in the metastatic stage A phase III clinical study of the efficacy and safety of chemotherapy-induced HER2 low expression breast cancer compared with the chemotherapy selected by the investigator .
-
Following PD-1, CAR-T, and ADC, another drug has become a new trend!
Time of Update: 2021-09-30
With more and more companies in the field of anti-double-antibodies, the phenomenon of R&D may appear in the future, the track will also become crowded, and the homogenization competition will become more intense.
-
CSCO2021 Professor Li Jin: New Hope for HER2 Positive Solid Tumors New ADC Drug MRG002 Phase I Study Announced
Time of Update: 2021-09-29
On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncolog
-
Kelun Pharmaceutical Updates TROP-2 ADC Clinical Data and Newly Declares a Class 1 New Drug
Time of Update: 2021-09-29
Another patient with pancreatic cancer had stable disease after receiving SKB264 treatment, and the disease control time reached 30.
From: CSCO, official microblog of Kelun PharmaceuticalIn terms of safety, all 18 patients reported adverse events (AEs).
-
CSCO2021 Professor Li Jin: New hope for HER2-positive solid tumors, Phase I study of new ADC drug MRG002 announced
Time of Update: 2021-09-29
On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncolo
-
my country's first original ADC new drug Rongchang Biological Vidicuzumab is planned to be included in breakthrough therapy
Time of Update: 2021-08-16
On June 9th, the State Food and Drug Administration issued an announcement on the approval of the listing of vedicitumumab for injection, which is applicable to HER2 overexpression locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) that has received at least two systemic chemotherapy ) Treatment of patients .
-
Roche's ADC drug Hersele's new indication is approved again to protect the long-term survival of patients with HER2-positive advanced breast cancer
Time of Update: 2021-08-11
On June 23, Roche Pharmaceuticals China announced that the State Administration of Medicines has officially approved the innovative targeted drug Hercelium® (English trade name: Kadcyla®, generic nam
-
Lepu Biologics TF ADC submits a clinical application for new drugs in China
Time of Update: 2021-07-06
On June 7, the new drug clinical trial application (IND) of the antibody-conjugated drug MRG004A that targets tissue factor (TF) submitted by Shanghai Miac, a wholly-owned subsidiary of Lepu Bio, was accepted by CDE .
-
New double-anti-ADC and ADC players enter the game, and financing companies "challenge" leading position in May
Time of Update: 2021-07-06
Based on the three major medical R&D technology platforms of ElpisourceTM, a new target discovery platform, ImmunosineTM, an in vitro drug efficacy screening platform for tumor immunity, and AbLegoTM, a double-antibody design platform, Kewang Pharmaceutical’s R&D pipeline covers a wide range of tumor immunity and is in the field of natural immunity with great potential.
-
Gilead Trodelvy reports frequent good news, Trop-2 targeted ADC drug transactions frequently appear
Time of Update: 2021-07-03
In April 2019, Genting Xinyao and Immunomedics reached a licensing agreement to obtain the development, registration and commercialization rights and interests of the drug in Greater China, South Korea and some Southeast Asian countries and regions, with a transaction amount of up to 835 million US dollars .